Thymogen in the United States

Legal status, what it is, and the listed suppliers in the United States that list it.

Legal status in the United States

Not an approved medicine.

As understood at 2026-09-22. Verify with the FDA.

What Thymogen is

Thymogen is a synthetic two-amino-acid peptide, glutamic acid joined to tryptophan, identified in the 1980s as an active component of thymalin, a calf-thymus extract. It belongs to the series of short 'bioregulator' peptides developed by Vladimir Khavinson's institute in St Petersburg. It has been registered as an immunomodulating drug in Russia since 1990. It is not a licensed medicine in the UK, US or Australia.

Full Thymogen page: targets and research →

Listed suppliers in the United States

None of the suppliers we list in the United States list Thymogen.

Clinical Research

Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats

Anisimov VN, Khavinson VK, Morozov VG (2000). Biogerontology. animal female outbred rats, n=76, followed to natural death

Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line

Avolio F, Martinotti S, Khavinson VK, et al. (2022). International Journal of Molecular Sciences. in-vitro human THP-1 monocyte/macrophage cell line

The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity

Khavinson VK, Linkova NS, Chalisova NI, Ivko OM (2021). Biology Bulletin Reviews. review n/a (review)

Thymodepressin—Unforeseen Immunosuppressor

Deigin VI, Vinogradova YE, Vinogradov DL, Krasilshchikova MS, Ivanov VT (2021). Molecules. animal SJL/J mice in a mercury-induced autoimmunity model (5–8 per group); hybrid mice in a graft-versus-host model